InvestorsHub Logo
Followers 23
Posts 1033
Boards Moderated 0
Alias Born 05/22/2014

Re: plusorminus post# 73193

Thursday, 08/10/2017 9:02:11 PM

Thursday, August 10, 2017 9:02:11 PM

Post# of 144814
Here is the reality: https://www.facebook.com/austrianova/photos/a.806632359368640.1073741832.747212361977307/1616942508337617/?type=3&theater

This is posted on Austrianova's FB page. Austrianova has a new partner. We now know this definitively.

A new partner is very significant for PharmaCyte, Austrianova and Cell-in-a-Box®.

PharmaCyte Biotech owns the exclusive worldwide rights to use the Cell-in-a-Box® encapsulation technology as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, are being built.

More noteworthy from a forward revenue standpoint, PharmaCyte also owns the exclusive worldwide rights to use the Cell-in-a-Box® technology for the development of a treatment for Type 1 & Type 2 diabetes. It makes sense for the world's largest pharmaceutical company, Johnson & Johnson, to want the world's best encapsulation technology, Cell-in-a-Box®, to treat one of the world's largest health problems: diabetes.









Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News